111 related articles for article (PubMed ID: 12039580)
1. Preparation, characterization, molecular modeling and in vitro activity of paclitaxel-cyclodextrin complexes.
Alcaro S; Ventura CA; Paolino D; Battaglia D; Ortuso F; Cattel L; Puglisi G; Fresta M
Bioorg Med Chem Lett; 2002 Jun; 12(12):1637-41. PubMed ID: 12039580
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins.
Sharma US; Balasubramanian SV; Straubinger RM
J Pharm Sci; 1995 Oct; 84(10):1223-30. PubMed ID: 8801338
[TBL] [Abstract][Full Text] [Related]
3. 2-Hydroxypropyl-β-cyclodextrin-modified SLN of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells.
Baek JS; Cho CW
J Pharm Pharmacol; 2013 Jan; 65(1):72-8. PubMed ID: 23215690
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of water-solubility and bioactivity of paclitaxel using modified cyclodextrins.
Hamada H; Ishihara K; Masuoka N; Mikuni K; Nakajima N
J Biosci Bioeng; 2006 Oct; 102(4):369-71. PubMed ID: 17116587
[TBL] [Abstract][Full Text] [Related]
5. Monte Carlo docking simulations of cyclomaltoheptaose and dimethyl cyclomaltoheptaose with paclitaxel.
Kim H; Choi J; Kim HW; Jung S
Carbohydr Res; 2002 Mar; 337(6):549-55. PubMed ID: 11890892
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel-Loaded β-Cyclodextrin-Modified Poly(Acrylic Acid) Nanoparticles through Multivalent Inclusion for Anticancer Therapy.
Yuan S; Chen J; Sheng J; Hu Y; Jiang Z
Macromol Biosci; 2016 Mar; 16(3):341-9. PubMed ID: 26611878
[TBL] [Abstract][Full Text] [Related]
7. Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles.
Agüeros M; Zabaleta V; Espuelas S; Campanero MA; Irache JM
J Control Release; 2010 Jul; 145(1):2-8. PubMed ID: 20347897
[TBL] [Abstract][Full Text] [Related]
8. Stability of paclitaxel-loaded solid lipid nanoparticles in the presence of 2-hydoxypropyl-β-cyclodextrin.
Baek JS; Kim BS; Puri A; Kumar K; Cho CW
Arch Pharm Res; 2016 Jun; 39(6):785-93. PubMed ID: 27146520
[TBL] [Abstract][Full Text] [Related]
9. Liposomes encapsulating native and cyclodextrin enclosed paclitaxel: Enhanced loading efficiency and its pharmacokinetic evaluation.
Bhatt P; Lalani R; Vhora I; Patil S; Amrutiya J; Misra A; Mashru R
Int J Pharm; 2018 Jan; 536(1):95-107. PubMed ID: 29175440
[TBL] [Abstract][Full Text] [Related]
10. Comparative study on inclusion complexation of maltosyl-beta-cyclodextrin, heptakis(2,6-di-O-methyl)-beta-cyclodextrin and beta-cyclodextrin with fucosterol in aqueous and solid state.
Acartürk F; Imai T; Saito H; Ishikawa M; Otagiri M
J Pharm Pharmacol; 1993 Dec; 45(12):1028-32. PubMed ID: 7908969
[TBL] [Abstract][Full Text] [Related]
11. Docking experiments showing similar recognition patterns of paclitaxel when interacting with different macromolecular targets.
Alcaro S; Battaglia D; Ortuso F
Farmaco; 2003 Sep; 58(9):691-8. PubMed ID: 13679162
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of paclitaxel-conjugated β-cyclodextrin polyrotaxane and its antitumor activity.
Yu S; Zhang Y; Wang X; Zhen X; Zhang Z; Wu W; Jiang X
Angew Chem Int Ed Engl; 2013 Jul; 52(28):7272-7. PubMed ID: 23740531
[No Abstract] [Full Text] [Related]
13. Enhancement of the antiinflammatory effect of ethyl 4-biphenylyl acetate in ointment by beta-cyclodextrin derivatives: increased absorption and localized activation of the prodrug in rats.
Arima H; Adachi H; Irie T; Uekama K; Pitha J
Pharm Res; 1990 Nov; 7(11):1152-6. PubMed ID: 2293214
[TBL] [Abstract][Full Text] [Related]
14. Controlled Release, Intestinal Transport, and Oral Bioavailablity of Paclitaxel Can be Considerably Increased Using Suitably Tailored Pegylated Poly(Anhydride) Nanoparticles.
Calleja P; Espuelas S; Vauthier C; Ponchel G; Irache JM
J Pharm Sci; 2015 Sep; 104(9):2877-86. PubMed ID: 25600579
[TBL] [Abstract][Full Text] [Related]
15. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats.
Arima H; Yunomae K; Miyake K; Irie T; Hirayama F; Uekama K
J Pharm Sci; 2001 Jun; 90(6):690-701. PubMed ID: 11357172
[TBL] [Abstract][Full Text] [Related]
16. Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus.
Arima H; Yunomae K; Hirayama F; Uekama K
J Pharmacol Exp Ther; 2001 May; 297(2):547-55. PubMed ID: 11303042
[TBL] [Abstract][Full Text] [Related]
17. Solid lipid nanoparticles of paclitaxel strengthened by hydroxypropyl-β-cyclodextrin as an oral delivery system.
Baek JS; So JW; Shin SC; Cho CW
Int J Mol Med; 2012 Oct; 30(4):953-9. PubMed ID: 22859311
[TBL] [Abstract][Full Text] [Related]
18. In vivo toxicity and bioavailability of Taxol and a paclitaxel/beta-cyclodextrin formulation in a rat model during HIPEC.
Bouquet W; Ceelen W; Adriaens E; Almeida A; Quinten T; De Vos F; Pattyn P; Peeters M; Remon JP; Vervaet C
Ann Surg Oncol; 2010 Sep; 17(9):2510-7. PubMed ID: 20339948
[TBL] [Abstract][Full Text] [Related]
19. Stabilizing and solubilizing effects of sulfobutyl ether beta-cyclodextrin on prostaglandin E1 analogue.
Uekama K; Hieda Y; Hirayama F; Arima H; Sudoh M; Yagi A; Terashima H
Pharm Res; 2001 Nov; 18(11):1578-85. PubMed ID: 11758766
[TBL] [Abstract][Full Text] [Related]
20. In vitro cytotoxicity of paclitaxel/beta-cyclodextrin complexes for HIPEC.
Bouquet W; Boterberg T; Ceelen W; Pattyn P; Peeters M; Bracke M; Remon JP; Vervaet C
Int J Pharm; 2009 Feb; 367(1-2):148-54. PubMed ID: 18938234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
